Hi tuck, Sten & all - thx for an even handed pov. Not a biotechie, I appreciate folks like you two to shed light in this area. In a way, I think the market feels the same way --- and thus price CEGE accordingly. That said, unless AAV is a total blind alley, it appears the potential of 80 patents and 360 apps patents alone are worth the risk of CEGE currency, before we factor in the tangible asset of cash and mark to market. An occasional few million from the JTC doesn't hurt either <g>. The question is, would CEGE try to develop any product? Or would she try to leverage her IPR? If recent approach be the guide, the latter seems to be the direction. And, IMHO, rightly so. At the very least, low burn rate helps to her to weather the ups and downs. More, it will provide the best bang for the buck, so to speak. With such a strong balance sheet, it is not at all unreasonable for the big boys to swallow CEGE for her IFR for a small price.
best, Bosco |
